Fig. 10From: An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countriesTimeline from regulatory approval (either EMA or Health Canada) and reimbursement. AB, Alberta; BC, British Columbia; MB, Manitoba; NB, New Brunswick; NL, Newfoundland; NS, Nova Scotia; ON, Ontario; PE, Prince Edward Island; QC, Quebec; SK, SaskatchewanBack to article page